Clinical trial
Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
NCT00435916 · Seagen Inc., Industry · Completed
Key facts
| NCT number | NCT00435916 |
|---|---|
| Title | Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma |
| Official title | A Phase II Study of SGN-40 (Anti-huCD40 mAb) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) |
| Lead sponsor | Seagen Inc., Industry |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin |
| Intervention type | Drug |
| Interventions | SGN-40 |
| Enrollment | 46 |
| Start date | Dec 1, 2006 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2009 |
| First posted | Feb 16, 2007 |
| Last update posted | Jan 7, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: